Vascular Solutions
Integrated cardiovascular imaging and analysis platform
Company profile
Company profile
Philips Medical Systems is a global healthcare technology company that develops and deploys artificial intelligence-enabled solutions across the continuum of care. The company's AI strategy focuses on four key areas: streamlining workflows and operations by automating administrative and repetitive tasks, providing clinical insights and intelligence to empower healthcare professionals with actionable information at the point of care, expanding the reach of patient care to underserved communities and home settings, and supporting personalized self-care with tailored guidance. Philips offers an extensive portfolio spanning medical imaging (CT, MRI, ultrasound), image-guided therapy, patient monitoring, and diagnostic informatics across radiology, cardiology, oncology, and digital pathology. The company is committed to responsible AI development guided by principles of well-being, human oversight, safety, fairness, transparency, security, privacy, and sustainability. With over 135 years of innovation history, Philips partners with health systems, clinics, and healthcare providers worldwide to address challenges including staff shortages, administrative overload, and increasing patient demand from aging populations. The company maintains a strong focus on clinical validation, regulatory compliance, and ensuring healthcare professionals retain ultimate decision-making authority when using AI-enabled features.
Company description Philips Medical Systems DMC official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Embedded · Hybrid deployment with recorded integration context.
Recorded integration context: Cerner, Epic, Hospital information systems, PACS systems.
Company milestones
FDA 510(k) clearance for AI-Powered SmartHeart (March 2026), FDA clearance for Cardiovascular Workspace (November 2025), FDA clearance for SmartSpeed Precise Dual AI Software (July 2025), NVIDIA collaboration announced (May 2025), ITEA excellence award for IWISH project (September 2025), alliance with WellSpan Health (June 2026)
Partnerships
02 · Flagship portfolio
Selected source-backed Company products and the available commercial context.
Integrated cardiovascular imaging and analysis platform
Integrated diagnostics platform uniting patient care across specialties
AI-powered automated cardiac measurements for routine echocardiography exams
AI-powered left ventricle wall motion assessment in standard 17-segment bullseye display
Semi-automated 3D mitral valve anatomy and morphology analysis
Semi-automated right ventricle volume and ejection fraction measurements
AI-powered automatic Doppler flow profile classification for workflow enhancement
End-to-end patient monitoring with live streaming device data
Advanced CT reconstruction technique reducing dose, lowering noise, and improving low-contrast detectability
03 · Research intelligence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · Jul 1, 2025
X-ray dark-field chest radiography: a reader study to evaluate the diagnostic quality of attenuation chest X-rays from a dual-contrast scanning prototype.European radiology · Aug 1, 2023
Erratum: "Dosimetry on first clinical dark-field chest radiography" Med Phys 48(10), 6152-6159.Medical physics · Jul 1, 2022
X-ray dark-field chest imaging for detection and quantification of emphysema in patients with chronic obstructive pulmonary disease: a diagnostic accuracy study.The Lancet. Digital health · Nov 1, 2021
Dosimetry on first clinical dark-field chest radiography.Medical physics · Oct 1, 2021
Imaging features in post-mortem x-ray dark-field chest radiographs and correlation with conventional x-ray and CT.European radiology experimental · Jul 11, 2019
Clinical validation
No linked records are currently available.
Regulatory
K233662 · 510k · Jun 13, 2024
Philips EPIQ Diagnostic Ultrasound System, Philips Affiniti Diagnostic Ultrasound SystemK212704 · 510k · Sep 24, 2021
EPIQ Series Diagnostic Ultrasound System, Affiniti Series Diagnostic Ultrasound SystemK211597 · 510k · Sep 8, 2021
04 · Company-reported outcomes
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Precise Position feature
CT workflow automation
Automated patient positioning
Auto Measure feature
Precise Image CT reconstruction
Strategic alliance to transform healthcare delivery using AI and innovative solutions
05 · Leadership
Leadership profiles and professional links from the current Company record.
Roy Jakobs
CEO
Shez Partovi
Chief Innovation Officer
Atul Gupta
Dr.
06 · Company updates
Recent articles published on Philips Medical Systems DMC's official website.
07 · HAIC coverage
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Curated official destinations from the active Company record.
09 · Market pathway
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.